U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07921316) titled 'Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple Doses' on Nov. 02.
Brief Summary: The main objective of this study is to compare the pharmacokinetics of maridebart cafraglutide administered as a single dose using two different subcutaneous (SC) presentations in participants with overweight or obesity after they have received escalating doses of the study drug.
Study Start Date: Nov. 09
Study Type: INTERVENTIONAL
Condition:
Obesity
Overweight
Intervention:
DRUG: Maridebart cafraglutide
Administered subcutaneously....